People searching “TB-500 side effects” want a straight answer: what can this do to me, how likely is it, and how bad can it get? Here is the honest headline: there are no published human safety studies of TB-500 itself. The reassuring “well tolerated” line that circulates online comes from clinical trials of a different, longer molecule — full-length thymosin β4 — given intravenously, short-term, under medical supervision. Everything else you will read about side effects is user report, not data. On top of that, laboratory research flags a real theoretical cancer-promotion concern.
This is a research-use-only reference and is not medical advice. TB-500 is not an approved medicine anywhere.
Chemistry first, because it drives everything else. Independent analyses of commercial “TB-500” products show the active ingredient is not whole thymosin β4 but a synthetic, N-terminally acetylated fragment of it — the 17–23 actin-binding region, Ac-LKKTETQ (Esposito et al., 2012; Ho et al., 2012). So when a seller cites “thymosin β4 clinical trials” as proof TB-500 is safe, that is a substitution the evidence does not support.
The three kinds of “side effect” you will read about
Almost every argument about TB-500 safety collapses because these get mixed together. They are not equivalent, and knowing which is which tells you how much weight to give any claim.
| Effect | Frequency / severity | Evidence source (type) |
|---|---|---|
| General / infusion-related adverse events | Infrequent, mild-to-moderate; no serious adverse events or dose-limiting toxicity in short-term dosing | Clinical — Ruff 2010; Wang 2021 (full-length Tβ4, IV, ≤14 days) |
| Anti-drug antibodies (immunogenicity) | Built into trial protocols as a monitored risk; peptides can provoke immune responses | Clinical — Wang 2021; trial NCT04555850 |
| Injection-site reactions, headache, fatigue, head-rush, appetite or fluid-retention changes | Commonly described, frequency unknown — usually reported as short-lived | Anecdotal — user reports and clinic blogs, no controlled data |
| Tumour-promoting activity (angiogenesis, anti-apoptosis, cell migration/EMT) | Serious but theoretical; observed in cell and tumour models, not reported as a human-trial side effect | Preclinical — Smart 2007; Xing 2021; Jin 2025 |
| Long-term / chronic self-injection effects | Unknown — no human data exist | Evidence gap (none identified) |
What the human trials actually found
In short Phase 1 dosing of full-length thymosin β4, adverse events were “infrequent, and mild or moderate,” with no serious adverse events and no dose-limiting toxicity (Ruff et al., 2010, DOI; Wang et al., 2021, DOI; indexed in PubMed). That is genuinely reassuring for that molecule, by that route, over that timeframe.
What it does not tell you is anything about weeks or months of subcutaneous self-injection of an unregulated fragment. Different molecule, different route, different duration, no supervision, no monitoring.
What people commonly report (and what that is worth)
Search results and clinic pages consistently describe the same short list: reactions at the injection site, headache, tiredness or lethargy for a day or two, a brief head-rush or light-headedness shortly after a dose, and occasional appetite changes or a sense of fluid retention. These reports are consistent enough to be worth knowing about.
They are also, without exception, uncontrolled. Nobody has measured how often they occur, whether they occur more than with a placebo injection, or whether they come from the peptide, the solvent, the injection technique or a contaminant in an unregulated product. Treat the list as “things to watch for,” not as a documented side-effect profile — and note that the effects a mislabelled or impure product could cause are not on any list, because nobody knows what is in it.
How long do side effects last?
There is no measured answer, because there is no study that followed them. In user reports, injection-site soreness and short-term tiredness are usually described as resolving within a day or two. That is the extent of what can honestly be said. The effects that genuinely matter here — immunogenicity and the theoretical cancer signal — are not the kind you would notice in a day or feel at all, which is precisely why the absence of monitoring is the risk.
The cancer question
This is the serious signal, and it is preclinical. The same properties that make thymosin β4 attractive for tissue repair — promoting angiogenesis, cell migration and survival while suppressing programmed cell death — are also mechanisms that can favour tumour growth. Reviews and mechanistic work describe Tβ4 driving angiogenesis and tumour progression (Smart et al., 2007; Xing et al., 2021), and a 2025 study reported that Tβ4 promotes breast-cancer proliferation, migration, EMT and angiogenesis, with high expression linked to worse clinical outcomes (Jin et al., 2025).
To be precise about what this is and is not: it is a laboratory finding, not a confirmed human side effect. No study has shown TB-500 causing cancer in a person. But it is exactly the kind of risk that “no long-term human data” leaves completely unmonitored — a plausible mechanism with no clinical outcome data in either direction.
Who is at higher risk / contraindications
- Anyone with active or prior cancer, or a strong family history: the documented pro-angiogenic and anti-apoptotic mechanisms are a theoretical concern with no human safety data to offset them (Smart 2007; Xing 2021; Jin 2025).
- Pregnant or breastfeeding individuals: uniformly excluded from thymosin β4 trials; no safety data.
- People with peptide or protein hypersensitivity: immunogenicity (anti-drug antibodies) is a recognised, protocol-monitored risk (Wang 2021).
- Tested or competitive athletes: TB-500 and thymosin β4 are prohibited in sport by WADA and by the equine authorities FEI and IFHA (Delcourt et al., 2024). Use risks sanctions independent of any health effect.
- Anyone who cannot verify product identity and purity: TB-500 circulates as non-authorised products sold online (Delcourt 2024), so contamination and mislabelling are unquantified additional risks.
What we do NOT know
For a research peptide like TB-500, the gaps are not a footnote — they are the main risk. Absence of evidence here means absence of safety monitoring, not evidence of safety.
- There is no completed human safety trial of the TB-500 fragment (Ac-LKKTETQ) itself.
- No data exist on the subcutaneous gray-market dosing and schedules people actually use.
- No long-term or chronic-use human data exist — the reassuring trials lasted days to a few weeks.
- No thymosin β4 product has been approved by the FDA or EMA for any use, despite years of trials (several of which were terminated or withdrawn).
- The cancer question is unanswered in humans: a plausible mechanistic risk with no clinical outcome data either way.
- Drug interactions, effects in people with chronic disease, and product-to-product variability are all uncharacterised.
Dosage & handling reference
Because TB-500 is not an approved medicine, there is no validated human dose — any figures you see are laboratory conventions, not clinical guidance. For reconstitution and unit-conversion documentation used in a research setting only, see our TB-500 dosage reference, the TB-500 5 mg vial protocol page and the general peptide dosage calculator. These tools exist to document handling accurately; they are not human-use instructions and do not imply the compound is safe or effective.
FAQ
Is TB-500 proven safe in humans?
No. There are no completed human safety trials of the TB-500 fragment. The only human tolerability data are for full-length thymosin β4 — a different molecule — tested short-term under supervision (Ruff 2010; Wang 2021).
What are the most commonly reported TB-500 side effects?
Injection-site reactions, headache, tiredness, brief light-headedness after a dose, and occasional appetite or fluid-retention changes. All of these come from user reports rather than controlled studies, so their true frequency is unknown and none has been shown to be caused by the peptide rather than by the injection, the solvent or product impurities.
How long do TB-500 side effects last?
No study has measured it. The short-term effects people describe — soreness, tiredness, headache — are typically reported as resolving within a day or two. The risks that matter most, immunogenicity and the theoretical cancer signal, would not produce noticeable symptoms at all.
Do the thymosin β4 clinical trials apply to TB-500?
Not directly. Commercial TB-500 is a synthetic 17–23 fragment (Ac-LKKTETQ), not whole thymosin β4 (Esposito 2012; Ho 2012), so trial results for the full peptide cannot be assumed to transfer.
Can TB-500 cause cancer?
There is no human evidence either way. Preclinical studies show thymosin β4 can promote angiogenesis, cell migration and tumour progression (Smart 2007; Xing 2021; Jin 2025), so the concern is real and simply unresolved. This is one reason the unknown long-term safety matters.
Does stacking TB-500 with BPC-157 change the risk?
It adds an unknown to an unknown. Neither compound has human safety data of its own, no study has examined the combination in people, and any interaction between them is uncharacterised. A stack cannot be safer than its least-studied component.
Will TB-500 show up on a drug test?
It can. TB-500 and thymosin β4 are on the WADA prohibited list, and analytical methods to detect them in athlete samples have been published (Delcourt et al., 2024). Anyone subject to testing should treat detection as a realistic outcome, not a remote one.
This article is for research documentation and general information only. It is not medical advice, and TB-500 is not an approved treatment. Consult a qualified healthcare professional before making any health decision.
